Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Auxilium Testim

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Auxilium's male hormone replacement therapy Testim (testosterone gel) clears FDA Oct. 31 for treatment of hypogonadism. The Testim clinical trials, involving 644 hypogonadal men, were the largest ever conducted in testosterone replacement therapy, Auxilium said. The gel uses Bentley's CPE-215 drug delivery technology, which is licensed to Auxilium. Testim is Auxilium's first commercial produc

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS002063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel